These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10747831)

  • 1. In vitro selected fluoroquinolone-resistant mutants of Citrobacter freundii: analysis of the quinolone resistance acquisition.
    Tavío M; Vila J; Ruiz J; Amicosante G; Franceschini N; Martín-Sánchez AM; de Anta MT
    J Antimicrob Chemother; 2000 Apr; 45(4):521-4. PubMed ID: 10747831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii.
    Navia MM; Ruiz J; Ribera A; de Anta MT; Vila J
    J Antimicrob Chemother; 1999 Dec; 44(6):743-8. PubMed ID: 10590274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates.
    Tavío MM; Vila J; Ruiz J; Ruiz J; Martín-Sánchez AM; Jiménez de Anta MT
    J Antimicrob Chemother; 1999 Dec; 44(6):735-42. PubMed ID: 10590273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased production of AmpC-type beta-lactamases associated with the development of resistance to quinolones in Citrobacter freundii strains.
    Tavío Pérez MM; Amicosante G; Franceschini N; Vila J; Ruiz J; Oratore A; Martín-Sánchez AM; Jiménez de Anta MT
    Microb Drug Resist; 1999; 5(4):235-40. PubMed ID: 10647079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the gyrA and parC genes associated with fluoroquinolone resistance in clinical isolates of Citrobacter freundii.
    Nishino Y; Deguchi T; Yasuda M; Kawamura T; Nakano M; Kanematsu E; Ozeki S; Kawada Y
    FEMS Microbiol Lett; 1997 Sep; 154(2):409-14. PubMed ID: 9311142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of quinolone resistance mechanisms in Neisseria gonorrhoeae isolates in vitro.
    Tanaka M; Sakuma S; Takahashi K; Nagahuzi T; Saika T; Kobayashi I; Kumazawa J
    Sex Transm Infect; 1998 Feb; 74(1):59-62. PubMed ID: 9634306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.
    Cohen SP; McMurry LM; Hooper DC; Wolfson JS; Levy SB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1318-25. PubMed ID: 2679373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains.
    Martínez-Martínez L; García I; Ballesta S; Benedí VJ; Hernández-Allés S; Pascual A
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1850-2. PubMed ID: 9661034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis.
    Chamberland S; Bayer AS; Schollaardt T; Wong SA; Bryan LE
    Antimicrob Agents Chemother; 1989 May; 33(5):624-34. PubMed ID: 2502066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Accumulation and efflux of quinolones by clinical isolates of Stenotrophomonas maltophilia].
    Sánchez P; Alonso A; Campanario E; Alós I; Martíinez JL
    Rev Esp Quimioter; 2000 Jun; 13(2):176-81. PubMed ID: 10918091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the outer membrane for quinolone resistance in enterobacteria.
    Dechène M; Leying H; Cullmann W
    Chemotherapy; 1990; 36(1):13-23. PubMed ID: 2106416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation in DNA gyrase of norfloxacin-resistant clinical isolates of Neisseria gonorrhoeae.
    Tanaka M; Otsuki M; Nishino T; Kobayashi I; Matsumoto T; Kumazawa J
    Genitourin Med; 1996 Aug; 72(4):295-7. PubMed ID: 8976839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of a Ceftazidime-Avibactam-Resistant
    Castanheira M; Arends SJR; Davis AP; Woosley LN; Bhalodi AA; MacVane SH
    mSphere; 2018 Sep; 3(5):. PubMed ID: 30258039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of quinolone susceptibility in Campylobacter jejuni associated with different gyrA mutations.
    McIver C; Hogan T; White P; Tapsall J
    Pathology; 2004 Apr; 36(2):166-9. PubMed ID: 15203753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased permeability and enhanced proton-dependent active efflux in the development of resistance to quinolones in Morganella morganii.
    Tavío MM; Vila J; Ruiz J; Martín Sánchez AM; Jiménez de Anta MT
    Int J Antimicrob Agents; 2000 Mar; 14(2):157-60. PubMed ID: 10720807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection and characterization of fluoroquinolone-resistant mutants of Campylobacter jejuni using enrofloxacin.
    Payot S; Cloeckaert A; Chaslus-Dancla E
    Microb Drug Resist; 2002; 8(4):335-43. PubMed ID: 12523631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.